Grifois

GRFS

Market cap $6.63B

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma firm Grifols to influence its share price.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Grifols demonstrates strong recovery, with leverage reduced to 4.2x and dividend reinstated, supporting a renewed investment case. GRFS posted robust Q2 2025 results: 7% revenue growth, 12.5% EBITDA growth, and near-record margins, reinforcing its global plasma leadership. Valuation remains compelling, with a new price target of €23/share and a 'BUY' rating, reflecting over 100% potential upside in coming years.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?